NCCAM PC-SPES Clinical Research Could Resume With “Clean” Product
This article was originally published in The Tan Sheet
Executive Summary
NIH's National Center for Complementary & Alternative Medicine could resume funding clinical research on PC-SPES if an independent manufacturer is able to develop an uncontaminated version of the proprietary herbal blend, NCCAM Director Stephen Straus, MD, suggested at the center's advisory council meeting in Rockville, Md. Aug. 26
You may also be interested in...
CAM Researcher Qualifications Review by IoM Cmte. Urged by Straus
The Institute of Medicine's Committee on the Use of Complementary & Alternative Medicine by the American Public should evaluate the different qualifications and knowledge sets CAM researchers bring to the study environment, NCCAM Director Stephen Straus, MD, said at the group's inaugural meeting in Washington, D.C. Feb. 27
NCCAM Future Grants May Focus More On Mind-Body, Less On Herbals
The National Center for Complementary & Alternative Medicine is considering shifting a greater percentage of its funding portfolio toward mind-body medicine and away from herbal medicines
Protocol Review, Clinical Trial Conduct Purview Of New NCCAM Office
NCCAM's Office of Clinical & Regulatory Affairs expects to use an FDA draft guidance on botanical drug products as a starting point for reviewing research protocols and overseeing clinical trials funded by the center, OCRA Director Jonathan Berman, MD/PhD, said Aug. 26